Comparison of the Efficacy of Buprenorphine and Clonidine in Detoxification of Opioid-dependents

Overview

Journal Addict Health

Date 2014 Feb 5

PMID 24494140

Citations 7

Authors

Hassan Ziaaddini

Mansooreh Nasirian

Nouzar Nakhaee

Affiliations

Soon will be listed here.

Abstract

Background: Since the number of drug users is increasing, applying a method of detoxification with fewer side effects during withdrawal from opioids and greater reliability seems to be necessary. In addition, without maintenance treatment, there will be limited success of treatment. This study aimed to compare success rates of detoxification with sublingual buprenorphine and clonidine and to evaluate addiction relapse in patients using naltrexone in a six-month follow-up.

Methods: This double-blind trial was carried out on opioid dependent patients in a psychiatric hospital in Kerman (Iran) during 2007-09. The subjects were randomly selected from individuals who had referred for detoxification. They were allocated to two groups to receive either clonidine (n = 21) or buprenorphine (n = 14). The success rates of the two methods were assessed at the end of the course and patients were discharged while prescribed with 25 mg daily use of naltrexone. They were followed up for six months and the continuous use of naltrexone and relapse of substance abuse were evaluated.

Findings: A total number of 35 patients entered the study. Success of detoxification with naltrexone was confirmed in all cases. One person (8.4%) in the clonidine group and no patient in the buprenorphine group had a clinical opiate withdrawal scale (COWS) score of more than 12 (P > 0.05). The mean levels of objective signs and subjective symptoms of withdrawal and the desire for drug abuse had significant reductions during detoxification period in both groups (P < 0.001). However, the difference in these variables between the two groups was not statistically significant (P > 0.05). Naltrexone was used for an average of one month in 43% and 64% of subjects in the clonidine and buprenorphine groups, respectively. In addition, 62% of patients in the clonidine group and 92.8% of subjects in the buprenorphine group received maintenance treatment. Nevertheless, the mean number of days staying in treatment was not significantly difference between the two groups (P > 0.05).

Conclusion: Buprenorphine is as effective as clonidine in controlling withdrawal symptoms. A greater percentage of patients detoxified by buprenorphine received maintenance treatment, but there was not a significant difference in relapse rates between the two methods.

Citing Articles

Sociodemographic and clinical profiles of individuals with opioid dependence syndrome presenting to a tertiary care center in Assam: A retrospective review.

Chakravarty P, Mahintamani T, Mukherjee D, Daimary P, Dutta H Indian J Psychiatry. 2025; 66(12):1165-1168.

PMID: 39867242 PMC: 11758967. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_907_24.

A Retrospective Comparison of the Effectiveness of Buprenorphine Versus Baclofen for Acute Opioid Withdrawal.

Hermenau M, Stamper B, Leung K, Pomm R, Guerrier C, Cammilleri J HCA Healthc J Med. 2023; 4(2):139-149.

PMID: 37424975 PMC: 10324876. DOI: 10.36518/2689-0216.1498.

Methadone, Buprenorphine, and Clonidine Attenuate Mitragynine Withdrawal in Rats.

Hassan R, Sreenivasan S, Muller C, Hassan Z Front Pharmacol. 2021; 12:708019.

PMID: 34322028 PMC: 8311127. DOI: 10.3389/fphar.2021.708019.

Pharmacological therapies for management of opium withdrawal.

Rahimi-Movaghar A, Gholami J, Amato L, Hoseinie L, Yousefi-Nooraie R, Amin-Esmaeili M Cochrane Database Syst Rev. 2018; 6:CD007522.

PMID: 29929212 PMC: 6513031. DOI: 10.1002/14651858.CD007522.pub2.

Buprenorphine for managing opioid withdrawal.

Gowing L, Ali R, White J, Mbewe D Cochrane Database Syst Rev. 2017; 2:CD002025.

PMID: 28220474 PMC: 6464315. DOI: 10.1002/14651858.CD002025.pub5.

References

Harrison L . The validity of self-reported drug use in survey research: an overview and critique of research methods. NIDA Res Monogr. 1997; 167:17-36. View

Charney D, Heninger G, Sternberg D, Hafstad K, Giddings S, Landis D . Adrenergic receptor sensitivity in depression. Effects of clonidine in depressed patients and healthy subjects. Arch Gen Psychiatry. 1982; 39(3):290-4. DOI: 10.1001/archpsyc.1982.04290030030005. View

Bickel W, Stitzer M, Bigelow G, Liebson I, Jasinski D, Johnson R . A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther. 1988; 43(1):72-8. DOI: 10.1038/clpt.1988.13. View

Gerra G, Leonardi C, DAmore A, Strepparola G, Fagetti R, Assi C . Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective study. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 30(2):265-72. DOI: 10.1016/j.pnpbp.2005.10.007. View

Vining E, Kosten T, KLEBER H . Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict. 1988; 83(5):567-75. DOI: 10.1111/j.1360-0443.1988.tb02576.x. View

Tompkins D, Bigelow G, Harrison J, Johnson R, Fudala P, Strain E . Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009; 105(1-2):154-9. PMC: 2774236. DOI: 10.1016/j.drugalcdep.2009.07.001. View

Gold M, Pottash A, SWEENEY D, KLEBER H . Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment. JAMA. 1980; 243(4):343-6. View

Jasinski D, Johnson R, Kocher T . Clonidine in morphine withdrawal. Differential effects on signs and symptoms. Arch Gen Psychiatry. 1985; 42(11):1063-6. DOI: 10.1001/archpsyc.1985.01790340041006. View

Bearn J, Bennett J, Martin T, Gossop M, Strang J . The impact of naloxone/lofexidine combination treatment on the opiate withdrawal syndrome. Addict Biol. 2001; 6(2):147-156. DOI: 10.1080/13556210020040226. View

10.

Digiusto E, Lintzeris N, Breen C, Kimber J, Mattick R, Bell J . Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. Addict Behav. 2005; 30(3):443-56. DOI: 10.1016/j.addbeh.2004.06.002. View

11.

OConnor P, Carroll K, Shi J, Schottenfeld R, Kosten T, Rounsaville B . Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med. 1997; 127(7):526-30. DOI: 10.7326/0003-4819-127-7-199710010-00004. View

12.

Abnet C, Saadatian-Elahi M, Pourshams A, Boffetta P, Feizzadeh A, Brennan P . Reliability and validity of opiate use self-report in a population at high risk for esophageal cancer in Golestan, Iran. Cancer Epidemiol Biomarkers Prev. 2004; 13(6):1068-70. View

13.

Ling W, Amass L, Shoptaw S, Annon J, Hillhouse M, Babcock D . A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005; 100(8):1090-100. PMC: 1480367. DOI: 10.1111/j.1360-0443.2005.01154.x. View

14.

Cheskin L, Fudala P, Johnson R . A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend. 1994; 36(2):115-21. DOI: 10.1016/0376-8716(94)90093-0. View

15.

Johnson R, Strain E, Amass L . Buprenorphine: how to use it right. Drug Alcohol Depend. 2003; 70(2 Suppl):S59-77. DOI: 10.1016/s0376-8716(03)00060-7. View

16.

Gowing L, Ali R, White J . Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2006; (2):CD002025. DOI: 10.1002/14651858.CD002025.pub3. View

17.

Wesson D, Ling W . The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003; 35(2):253-9. DOI: 10.1080/02791072.2003.10400007. View

18.

KOYUNCUOGLU H . The combination of tizanidine markedly improves the treatment with dextromethorphan of heroin addicted outpatients. Int J Clin Pharmacol Ther. 1995; 33(1):13-9. View

19.

Schneider U, Paetzold W, Eronat V, Huber T, Seifert J, Wiese B . Buprenorphine and carbamazepine as a treatment for detoxification of opiate addicts with multiple drug misuse: a pilot study. Addict Biol. 2010; 5(1):65-9. DOI: 10.1080/13556210071289. View

20.

Amass L, Bickel W, Higgins S, Hughes J . A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis. 1994; 13(3):33-45. DOI: 10.1300/j069v13n03_04. View